Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 14/07/2025 BST			5-day change	1st Jan Change
1,372.00 ^DKK	-0.44%		+5.66%	-8.07%

07-11	Baptista Research Begins Genmab Coverage at Outperform	MT
07-01	Genmab Announces Changes to Its Executive Committee	CI

GENMAB : Mixed Q1; guidance maintained

Published on 10/05/2025 at 16:02

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

Baptista Research Begins Genmab Coverage at Outperform	07-11	MT
Genmab Announces Changes to Its Executive Committee	07-01	CI
Genmab's Chief Legal Officer Steps Down; Successor Named	07-01	MT
UBS Lowers Price Target for Genmab to 2,500 Danish Kroner, Reiterates Buy Recommendation	06-25	FW
Genmab A/S, Q1 2025 Earnings Call, May 08, 2025	06-17
Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	06-16	MT
Genmab's Epcoritamab Combination Shows High Response Rates in Cancer Patients	06-16	MT
Genmab A/S Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (L) Eligible for Autologous Stem Cell Transplantation	06-15	CI
Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM	06-09
AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	06-09	MT
GENMAB : Beaten up share price offers an opportunity	06-06
Genmab's Rina-S shows promising efficacy in difficult-to-treat uterine cancer	06-03	FW
Sector Update: Health Care Stocks End Higher Late Afternoon	06-02	MT
Genmab Says New Trial Data Shows 'Encouraging Anti-Tumor Activity' for Rinatabart Sesutecan	06-02	MT
Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial	06-02	CI
RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN	05-30	FW
RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating	05-29	MT
Deutsche Bank lowers target price for Genmab to DKK 1,750 (1,900), reiterates buy recommendation	05-23	FW
Redburn lowers target price for Genmab to DKK 2,700 (2,750), reiterates buy recommendation - BN	05-23	FW
Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association Congress	05-14	CI
UBS lowers target price for Genmab to DKK 2,600 (2,700), reiterates buy recommendation	05-12	FW
GENMAB : Mixed Q1; guidance maintained	05-10
Nordea Bank Upgrades Genmab to Buy	05-09	MT
Nykredit lowers target price for Genmab to DKK 1,750 (2,000), reiterates buy recommendation - BN	05-09	FW
Nordea raises Genmab to buy (hold), target price SEK 2,009	05-09	FW

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,638

Sector

Biotechnology & Medical Research

Calendar

08-07 - Q2 2025 Earnings Release

More about the company